News & Info


Page 3 of 2812345...1020...Last »

April 18, 2016

Eye Drops for Wet AMD Enter Phase 3 Trials

Posted in: Latest News

Ohr Pharmaceutical has announced that the first patient has been enrolled in a Phase III clinical trial of the company’s lead drug candidate “Squalamine”, also known as OHR-102, for the treatment of neovascular age-related macular degeneration (wet AMD). “The Phase III clinical program will examine the potential of Squalamine, when administered as part of a combination therapy,
read more »

April 14, 2016

Smoking and AMD—Are E-Cigarettes the Answer?

Posted in: Health and Nutrition, Latest News, Research and Developments

by Dan Roberts You’ve heard it before: “Tobacco Smoking Is A Major Cause Of Age Related Macular Degeneration”. According to most research, individuals 65 years of age and over double their risk of developing age-related macular degeneration (AMD) if they smoke. Why? Because tobacco smoking: Reduces levels of plasma antioxidant, a substance in the blood
read more »

March 23, 2016

Hidden Disabilities: A Social Dilemma

Posted in: Daily Living

by Dan Roberts Margaret’s Story I was making my way down the sidewalk. I heard the clack-clack of skateboard wheels coming at me head-on. I couldn’t see which way to step, so I just froze in place, hoping the child would have good maneuvering skills. He didn’t. He collided with my bad hip, and his
read more »

March 22, 2016

Patient Access Network Foundation and Prevent Blindness Announce New Alliance to Provide Support for People Living With Eye Health Concerns

Posted in: Latest News

The Patient Access Network (PAN) Foundation and Prevent Blindness today announced that they are launching a new alliance to offer holistic support for people living with retinal vein occlusion, macular disease and uveitis. The alliance will enable the organizations to leverage the PAN Foundation’s eye health financial assistance programs and patient resources of Prevent Blindness
read more »

March 11, 2016

Sleeping Too Much Will *Not* Cause Blindness

Posted in: Latest News

Editorial by Dan Roberts Recent research has found an association between longer sleep duration and advanced dry age-related macular degeneration (dAMD), also known as geographic atrophy. This has been misconstrued by at least one media outlet to mean that too much sleep might actually cause the disease. That is absolutely untrue. According to the researchers, “Sleeping
read more »

March 6, 2016

Experimental Gene Therapies Still Raising Hopes

Posted in: Latest News, Research and Developments

Wills Eye Hospital has announced that it has treated the first RESCUE trial patient in the United States enrolled in an FDA-approved gene therapy vision research study. A product called GS010 (GenSight Biologics), can be injected right into the eye and, in a sense, “re-wire” or lower the patient’s risk for getting the disease. The patient has
read more »

March 1, 2016

Similarity of Anti-VEGF Drugs Confirmed For DME Treatment

Posted in: Latest News

A rigorous clinical trial has found that individuals with diabetic macular edema (DME), whose visual acuity is 20/50 or worse, gained more improvement with Eylea than with Avastin. Aside from that, no significant difference was found among the three anti-VEGF drugs (including Lucentis) in subjects with 20/32 or 20/40 vision at the start of treatment. By two years, 41 percent of participants in the
read more »

February 28, 2016

National Eye Institute Receives Funding Increase

Posted in: Latest News

Representatives from Prevent Blindness travel annually to Washington D.C. to advocate for Congressional support of programs and research for the visually impaired. The time spent on Capitol Hill has paid off this year with passage of the Consolidated Appropriations Act of 2016, signed by President Obama in December. Funding has taken some hard hits over
read more »

February 27, 2016

Large Study Shows 1 in 5 People With Vision Loss Experience Hallucinations

Posted in: Eye Conditions, Latest News

A new study conducted by the Canadian National Institute for the Blind (CNIB) has found that one in five Canadians with vision loss who were surveyed experience visual hallucinations, known as Charles Bonnet Syndrome (CBS). The study, titled “Prevalence of visual hallucinations in a national low vision client population”, published in the most recent issue
read more »

February 27, 2016

Future Sustained Drug Delivery Methods for Choroidal Neovascularization

Posted in: Latest News, Research and Developments

During the American Academy of Ophthalmology’s Retina Subspecialty Day in 2015, Peter K. Kaiser, MD, described six alternative methods being looked at for delivery of anti-VEGF drugs into the retinas of individuals experiencing choroidal neovascularization (CNV). Periodic intraocular injections are currently the only procedure for halting damaging blood vessel growth and leakage. Injections are expensive, time-consuming, and burdensome on the patients, so
read more »

February 27, 2016

Low Vision Rehabilitation Needs More Emphasis on Communication and Social Skills

Posted in: Daily Living, Low Vision Rehabilitation

Lea Hyvärinen, MD, PhD (Honorary Professor, Rehabilitation Sciences at Rehabilitation and Education in Blindness or Impairment of Vision in Dortmund, Germany) has described social difficulties caused by types of blindness and visual impairment. In her paper, “Effect of Vision Loss on Communication and Social Skills” she writes that “many problems in communication and social skills are due to misunderstandings
read more »

February 16, 2016

Eye Spy on the App Store

Posted in: Latest News

In collaboration with Prevent Blindness, Regeneron has developed Eye Spy, an app for those with low vision. Download it today! http://ow.ly/YlC5J The Eye Spy app is designed for patients with low vision. The app provides the opportunity for patients and caregivers to learn about their condition and create a community. What You’ll Find In This
read more »

February 15, 2016

New Combination Therapy Treats Retinal Damage in Diabetics

Posted in: Latest News, Research and Developments

Aerpio Therapeutics, Inc. has announced promising results from their “TIME-2” study of  AKB-9778 as a treatment for diabetic retinopathy (DR). AKB-9778 alone and in combination with Lucentis® (ranibizumab) improved underlying retinopathy by 10.0%, and 11.4% compared to 8.8% of patients receiving Lucentis® alone. The clinical findings were presented by Pravin U. Dugel, M.D., at the
read more »

February 10, 2016

AVA-101 May Extend Time Between Wet AMD Treatments

Posted in: Latest News, Research and Developments

In 2014, Avalanche Biotechnologies postulated that a single injection of a new gene therapy treatment could possibly stop blood vessel growth and leakage in the wet form of Age-Related Macular Degeneration (AMD) for several years. A single injection of a drug called AVA-101 (aka sFlt-1) could create a kind of biofactory that continuously secretes a therapeutic protein
read more »

February 5, 2016

High Dose Statins May Be Effective In Treating Dry AMD

Posted in: Latest News, Research and Developments

Researchers at Massachusetts Eye and Ear/Harvard Medical School and the University of Crete have found that high doses of statins (cholesterol-lowering medications) can effectively reduce the number of soft drusen deposits in retinas of people with dry age-related macular degeneration (dAMD). The findings from their phase I/II clinical trial were published in the recent issue of
read more »

Page 3 of 2812345...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann